CA3092747A1 - Pyrrolidineamide derivatives and uses thereof - Google Patents
Pyrrolidineamide derivatives and uses thereof Download PDFInfo
- Publication number
- CA3092747A1 CA3092747A1 CA3092747A CA3092747A CA3092747A1 CA 3092747 A1 CA3092747 A1 CA 3092747A1 CA 3092747 A CA3092747 A CA 3092747A CA 3092747 A CA3092747 A CA 3092747A CA 3092747 A1 CA3092747 A1 CA 3092747A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- alkoxy
- disease
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810192198 | 2018-03-08 | ||
| CN201810192198.6 | 2018-03-08 | ||
| PCT/CN2019/077249 WO2019170115A1 (en) | 2018-03-08 | 2019-03-07 | Pyrrolidineamide derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3092747A1 true CA3092747A1 (en) | 2019-09-12 |
Family
ID=67845842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092747A Pending CA3092747A1 (en) | 2018-03-08 | 2019-03-07 | Pyrrolidineamide derivatives and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11225460B2 (https=) |
| EP (1) | EP3762364B1 (https=) |
| JP (1) | JP7405756B2 (https=) |
| CN (1) | CN110240557B (https=) |
| AU (1) | AU2019230883B2 (https=) |
| CA (1) | CA3092747A1 (https=) |
| SG (1) | SG11202008543RA (https=) |
| WO (1) | WO2019170115A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240317681A1 (en) * | 2020-07-07 | 2024-09-26 | Sunshine Lake Pharma Co., Ltd. | Pyrrolidine amide derivative salt and use thereof |
| CN113896671B (zh) * | 2020-07-07 | 2023-06-09 | 广东东阳光药业有限公司 | 吡咯烷酰胺衍生物的盐及其用途 |
| CN113896670B (zh) * | 2020-07-07 | 2023-06-09 | 广东东阳光药业有限公司 | 吡咯烷酰胺衍生物的盐及其用途 |
| CN114573491B (zh) * | 2020-12-01 | 2023-12-08 | 广东东阳光药业股份有限公司 | 吡咯烷酰胺衍生物的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| WO2000033788A2 (en) | 1998-12-11 | 2000-06-15 | American Biogenetic Sciences Inc. | Substituted nitrogen heterocyclic compounds and therapeutic uses thereof |
| FR2799461B1 (fr) | 1999-10-11 | 2002-01-04 | Sod Conseils Rech Applic | Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments |
| MY134480A (en) * | 2002-09-20 | 2007-12-31 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| EP1524265A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| WO2006013049A2 (en) * | 2004-08-02 | 2006-02-09 | F.Hoffmann-La Roche Ag | Benzyloxy derivatives as maob inhibitors |
| US7501528B2 (en) | 2005-03-15 | 2009-03-10 | Hoffmann-La Roche Inc. | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives |
| US20070078172A1 (en) | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| BRPI0821026A2 (pt) | 2007-12-19 | 2015-06-16 | Newron Pharmaceutical S P A | Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos |
| CA2886904A1 (en) * | 2012-10-02 | 2014-04-10 | Cyril Montagne | Pyrrolidines |
| EP3601255A1 (en) | 2017-03-21 | 2020-02-05 | AbbVie Deutschland GmbH & Co. KG | Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical |
-
2019
- 2019-03-07 EP EP19764310.9A patent/EP3762364B1/en active Active
- 2019-03-07 JP JP2020546886A patent/JP7405756B2/ja active Active
- 2019-03-07 US US16/977,487 patent/US11225460B2/en active Active
- 2019-03-07 AU AU2019230883A patent/AU2019230883B2/en active Active
- 2019-03-07 SG SG11202008543RA patent/SG11202008543RA/en unknown
- 2019-03-07 CA CA3092747A patent/CA3092747A1/en active Pending
- 2019-03-07 WO PCT/CN2019/077249 patent/WO2019170115A1/en not_active Ceased
- 2019-03-07 CN CN201910170019.3A patent/CN110240557B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110240557A (zh) | 2019-09-17 |
| WO2019170115A1 (en) | 2019-09-12 |
| CN110240557B (zh) | 2023-05-09 |
| AU2019230883A1 (en) | 2020-09-24 |
| EP3762364A1 (en) | 2021-01-13 |
| JP7405756B2 (ja) | 2023-12-26 |
| US20210053918A1 (en) | 2021-02-25 |
| AU2019230883B2 (en) | 2024-02-01 |
| JP2021515019A (ja) | 2021-06-17 |
| EP3762364B1 (en) | 2023-08-23 |
| SG11202008543RA (en) | 2020-10-29 |
| US11225460B2 (en) | 2022-01-18 |
| EP3762364A4 (en) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11285153B2 (en) | Substituted pyrimidine piperazine compound and use thereof | |
| US11858910B2 (en) | Pyridinylmethylenepiperidine derivatives and uses thereof | |
| CN110041331B (zh) | 苯乙烯基黄嘌呤衍生物及其用途 | |
| AU2019230883B2 (en) | Pyrrolidineamide derivatives and uses thereof | |
| WO2020216152A1 (en) | 8-substituted aryl vinyl xanthine derivatives and uses thereof | |
| CN112300165B (zh) | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 | |
| WO2020125779A1 (en) | 8-substituted styryl xanthine derivatives and uses thereof | |
| CN112010818B (zh) | 吗啉酰胺衍生物及其用途 | |
| CN111072604B (zh) | α-氨基酰胺衍生物及其用途 | |
| CN108912029B (zh) | 含氮杂环酰胺衍生物及其用途 | |
| CN111018856B (zh) | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 | |
| CN111072676B (zh) | 含氮稠合三环衍生物及其用途 | |
| HK40036563B (en) | Pyrrolidineamide derivatives and uses thereof | |
| HK40036563A (en) | Pyrrolidineamide derivatives and uses thereof | |
| CN110938064B (zh) | N-取代哌啶酰胺衍生物及其用途 | |
| CN118063444A (zh) | 氮杂环丁烷酰胺衍生物及其用途 | |
| CN118063445A (zh) | 吡咯烷酰胺衍生物及其用途 | |
| HK40027192A (en) | Substituted pyrimidine piperazine compound and use thereof | |
| HK40027192B (en) | Substituted pyrimidine piperazine compound and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231002 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241024 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250113 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250113 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250113 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250214 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250224 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250706 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250706 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260112 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260302 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260302 |